167423-70-3

Upstream product

• 169825-26-7 D-<2-<(tert-butyldimethylsilyl)oxy>-1-<3-(allyloxy)phenyl>ethyl>amine 
• 185112-18-9 (2R,4R)-3-<2-azido-2-<3-(allyloxy)phenyl>-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 
• 185112-20-3 (R)-(3-Allyloxy-phenyl)-azido-acetic acid methyl ester 
• 185112-19-0 (R)-(3-Allyloxy-phenyl)-azido-acetic acid 
• 185112-21-4 (R)-(3-Allyloxy-phenyl)-amino-acetic acid methyl ester 
• 185112-17-8 (R)-2-(3-Allyloxy-phenyl)-2-amino-ethanol 
• 167423-69-0 {(S)-1-[(R)-1-(3-Allyloxy-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-ethylcarbamoyl]-ethyl}-carbamic acid allyl ester 

Downstream Products

• 185112-24-7 {(R)-1-[(R)-1-{(S)-1-[(R)-2-(tert-Butyl-dimethyl-silanyloxy)-1-(3-hydroxy-phenyl)-ethylcarbamoyl]-ethylcarbamoyl}-2-(4-fluoro-3-nitro-phenyl)-ethylcarbamoyl]-3-methyl-butyl}-methyl-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Palladium catalyzed reductive deprotection of alloc: Transprotection and peptide bond formation

N-allyloxycarbonyl group could be efficiently removed using sodium borohydride as hydride donor in the presence of catalytic amount of palladium (0). The conditions were applied to chemoselective protecting group transformation (transprotection) and peptide bond formation.

Synthesis of modified carboxyl binding pockets of vancomycin and teicoplanin

Sixteen-membered macrocycle 3 and 16+14 bicyclic compound 4, incorporating a terminal primary hydroxyl group in the peptide sequence, have been designed and synthesized. The syntheses feature the use of an efficient cycloetherification based on an intramolecular S(N)Ar reaction for the formation of biaryl ether bonds. Cyclization of linear tetrapeptide 30, prepared via a convergent [2+2] segment coupling between 26 and 29, gave macrocycle 31 (P configuration) as a single isolable atropisomer. Removal of the Boc protecting group afforded the modified carboxyl binding pocket of vancomycin 3. A sequential 2-fold intramolecular S(N)Ar reaction has been used to construct the model bicyclic system (i.e. 4) of the D-O-E-F-O-G ring of teicoplanin. Cyclization conditions (CsF, DMF, room temperature) are sufficiently mild that the configuration of the racemization-prone arylglycine residue was not affected. Chiral building blocks such as D-(1R)-[2-[(tert-butyldimethylsilyl)oxy]1-[3-(allyloxy)phenyl]ethyl]am ine 16, and L-(S)-N-Boc-[3-(isopropyloxy)phenyl]glycine (32) were synthesized employing Evans' asymmetric azidation method, while L-(S)-4-fluoro-3-nitrophenylalanine methyl ester 23 was prepared using Schollkopf's bislactim ether as chiral glycine template. Compound 3 showed interesting conformational properties compared to vancomycin and its binding with Ac-D-Ala was studied by NMR titration experiments. A dissociation constant (Kd) = 5 x 10-4) was calculated by a curve fitting method. Compound 4 is currently the most advanced synthetic intermediate toward the total synthesis of teicoplanin.